| ¼ò½é£º   
	²¿·ÝÖÐÎÄÑÎËáÍò¹ÅÃ¹ËØ´¦·½×ÊÁÏ£¨½ö¹©²Î¿¼£©Ó¢ÎÄÃû£ºVancomycin Hydrochloride
 ÉÌÆ·Ãû£ºVancomycin
 ÖÐÎÄÃû£ºÑÎËáÍò¹ÅÃ¹ËØ¶³¸É×¢Éä¼Á
 Éú²úÉÌ£ºÑÎÒ°ÒåÖÆÒ©
 Ò©Æ·¼ò½é
 Íò¹ÅÃ¹ËØ£¨Vancomycin£¬‰cËá¥Ð¥ó¥³¥Þ¥¤¥·¥óÉ¢£©ÊÇÒ»ÖÖ³£¼ûµÄ¾²Âö×¢ÉäÌÇëÄ¿¹ÉúËØ£¬¾³£ÓÃÓÚÖÎÁƽÐ×ö¼èÄÑËó¾úÏà¹ØÐÔ¸¹ÐºµÄÑÏÖØ³¦µÀ¸ÐȾ¡£
 ‰cËá¥Ð¥ó¥³¥Þ¥¤¥·¥óÉ¢0.5g
 ҩЧ·ÖÀàÃû³Æ
 ÌÇëÄ¿¹ÉúËØÖÆ¼Á
 Åú×¼ÈÕÆÚ£º2008Äê4ÔÂ
 Å·ÎÄÉ̘ËÃû
 Vancomycin
 Ò»°ãµÄÃû³Æ£º
 ¥Ð¥ó¥³¥Þ¥¤¥·¥ó‰cËá‰c£¨JAN£©£ÛÈÕ¾Ö£ÝVancomycin Hydrochloride
 ÂԺţºVCM
 »¯Ñ§Ãû£º(1S,2R,18R,19R,22S,25R,28R,40S)-50-[3-Amino-2,3,6-trideoxy-3-C-methyl-α-L-lyxo-hexopyranosyl-(1→2)-β-D-glucopyranosyloxy]-22-carbamoylmethyl-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(2R)-4-methyl-2-(methylamino) pentanoylamino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39] pentaconta-3,5,8,10,12(50),14,16,29,31,33(49),34,36,38,45,47-pentadecaene-40-carboxylic acid monohydrochloride
 ·Ö×Óʽ£ºC66H75Cl2N9O24・HCl
 ·Ö×ÓÁ¿£º1485.71
 »¯Ñ§˜‹Ôìʽ£º
 ÐÔ×´£º
 ËüÊǰ×É«·ÛÄ©¡£
 ËüÒ×ÈÜÓÚË®£¬Î¢ÈÜÓÚ¼×õ£°·£¬Î¢ÈÜÓÚ¼×´¼£¬Î¢ÈÜÓÚÒÒ´¼£¨95£©£¬¼¸ºõ²»ÈÜÓÚÒÒëæ¡£
 Ëü¾ßÓÐÎüʪÐÔ¡£
 È۵㣺
 ûÓÐÏÔʾȷ¶¨µÄÈ۵㡣£¨Ëü»áÔÚ120°C»ò¸ü¸ßµÄζÈÏÂÖð½¥±äÉ«²¢·Ö½â¡££©
 ÉóÅúÌõ¼þ
 ¿¼ÂÇËùʹÓõÄÉ豸£¬É豸µÄÌáÈ¡ÂʺÍÉ豸ÊýÁ¿£¬Çë²ÉÈ¡ÒÔÏ´ëÊ©¡£
 1.¼ÌÐø½øÐÐÊʵ±µÄÉÏÊкó¼à¶½£¨°üÀ¨Ãô¸ÐÐÔµ÷²é£©²¢ÊÕ¼¯ÐÅÏ¢¡£
 2.·ÖÎöÊÕ¼¯µ½µÄÐÅÏ¢£¬²¢¼ÌÐøÏòÒ½ÁÆ»ú¹¹Ìṩ±ØÒªµÄÐÅÏ¢£¬ÒÔÈ·±£ÕýȷʹÓá£
 3.ÿÄêÒ»´Î¸ù¾Ý¶¨ÆÚ°²È«±¨¸æÏòºñÉúÀͶ¯Ê¡Ìá½»±¨¸æ¡£
 ҩЧҩÀí
 1.¿¹¾ú×÷ÓÃ
 £¨1£©·¬Ã¹ËØÔÚÌåÍâ¶ÔÆÏÌÑÇò¾ú£¬¾§×´Ì壬·ÎÑ×£¬³¦Çò¾ú£¬crotridium£¨°üÀ¨¼èÄÑËó¾ú£©£¬·ÅÏß¾úºÍÈéËá¾ú¾ù¾ßÓп¹¾ú»îÐÔ¡£ Ëü¶Ô¸ïÀ¼ÊÏÒõÐÔ¾úûÓп¹¾ú»îÐÔ¡£
 £¨2£©Íò¹ÅÃ¹ËØÔÚÌåÍâ¶ÔÄͼ×ÑõÎ÷ÁֵĻÆÉ«ÆÏÌÑÇò¾ú£¨MRSA£©¾ßÓп¹¾ú»îÐÔ£¬ÓëÆäËû¿¹¾ú¼ÁÎÞ½»²æÄÍÒ©ÐÔ¡£´ËÍ⣬ÔÚʹÓÃMRSAµÄÌåÍâÑÇÅàÑøÊÔÑéÖУ¬¶ÔÍò¹ÅÃ¹ËØµÄÄÍÒ©ÐԽϵ͡£
 2.×÷ÓûúÀí
 Íò¹ÅÃ¹ËØµÄ×÷ÓùéÒòÓÚϸ¾úÖÐϸ°û±ÚºÏ³ÉµÄÒÖÖÆ£¬Æä¿¹¾ú×÷ÓþßÓÐɱ¾ú×÷Óá£Ëü»¹»á¸Ä±äϸ¾úϸ°ûĤµÄͨ͸ÐÔ¡£
 ÊÊÓ¦Ö¢
 1.´«È¾ÐÔ³¦Ñ×
 <ÊÊÓÃϸ¾úÖÖ>
 Äͼ×ÑõÎ÷ÁÖÄͼ×ÑõÎ÷ÁֵĻÆÉ«ÆÏÌÑÇò¾ú£¨MRSA£©£¬¼èÄÑËó¾ú
 <ÊÊÓ¦Ö¢>
 ´«È¾ÐÔ³¦Ñ×£¨°üÀ¨¼ÙĤÐԽ᳦Ñ×£©
 2.¹ÇËèÒÆÖ²¹ý³ÌÖеÄ賦µÀÃð¾ú
 Ó÷¨ÓëÓÃÁ¿
 1.´«È¾ÐÔ³¦Ñ×£¨°üÀ¨¼ÙĤÐԽ᳦Ñ×£©
 ËüÔÚʹÓÃǰ»áÈܽ⣬³ÉÈËͨ³£µÄ¼ÁÁ¿ÊÇÿÌì¿Ú·þËĴΣ¬Ã¿´Î0.125ÖÁ0.5g£¨µÎ¶¨¼Á£©¡£
 ¼ÁÁ¿¿ÉÒÔ¸ù¾ÝÄúµÄÄêÁ䣬ÌåÖØºÍÖ¢×´½øÐе÷Õû¡£
 2.¹ÇËèÒÆÖ²¹ý³ÌÖеÄ賦µÀÃð¾ú
 ÔÚʹÓÃʱÈܽ⣬ͨ³£³ÉÈËÒ»´Î0.5 g£¨Ð§¼Û£©Óë·ÇÎüÊÕÐÔ¿¹¾úºÍ¿¹Õæ¾ú¼ÁÿÌì¿Ú·þ4ÖÁ6´Î¡£
 ¼ÁÁ¿¿ÉÒÔ¸ù¾ÝÄúµÄÄêÁ䣬ÌåÖØºÍÖ¢×´½øÐе÷Õû¡£
 °ü×°
 ÑÎËá°à¹ÅÃ¹ËØ
 0.5g£º10Æ¿
 ÖÆÔìÉ̺ͷÖÏúÉÌ
 ÑÎÒ°ÒåÖÆÒ©ÓÐÏÞ¹«Ë¾
 ×¢£ºÒÔÉÏÖÐÎÄ×ÊÁϲ»¹»ÍêÕû£¬Ê¹ÓÃÕßÒÔÔ´¦·½×ÊÁÏΪ׼¡£
 ÍêÕû˵Ã÷Ê鸽¼þ£º
 https://www.info.pmda.go.jp/go/pack/6113001B1089_1_09/?view=frame&style=SGML&lang=ja
 |